功能近红外光谱用于识别轻度认知障碍和阿尔茨海默病:系统性审查
Haoyu Li1, Xi Yang2, Liang Gong3
1Department of Neurology, Chengdu Medical College, Chengdu Second People's Hospital, Chengdu, China.
Frontiers in neurology
|September 15, 2025
概括
功能近红外光谱学 (fNIRS) 在检测早期痴呆变化方面表现有前途. 这种神经成像技术可以高精度地区分轻度认知障碍 (MCI) 和阿尔茨海默氏病 (AD).
科学领域:
- 神经科学是一个神经科学.
- 医疗成像医学成像
- 生物医学工程 生物医学工程
背景情况:
- 神经退行性疾病,如阿尔茨海默氏症 (AD) 和轻度认知障碍 (MCI),涉及改变的大脑血液动力学.
- 功能近红外光谱 (fNIRS) 是一种非侵入性神经成像技术,用于测量血液动力学反应.
研究的目的:
- 评估fNIRS在识别早期痴呆相关变化的有效性.
- 使用fNIRS区分轻度认知障碍 (MCI) 和阿尔茨海默病 (AD).
主要方法:
- 通过PubMed和Web of Science进行了系统的文献审查,直到2024年2月.
- 在MCI和AD患者中使用fNIRS的研究是根据预先定义的标准进行选择的.
- 数据提取的重点是研究设计,fNIRS参数,实验范式和诊断标准.
主要成果:
- 包括58项研究,使用休息状态和/或基于任务的fNIRS范式.
- 在MCI和AD患者中观察到大脑激活,组织氧化指数 (TOI) 和功能连接 (FC) 的减少.
- 应用于fNIRS数据的机器学习模型在分类MCI和AD时达到高达90%的准确性.
结论:
- fNIRS显示出作为诊断和监测MCI和AD的工具的潜力.
- 需要进一步的研究,以充分确定fNIRS在痴呆症评估中的临床实用性.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
33.8K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
8.4K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825
